Log In Sign up
The largest database of trusted experimental protocols

Antibody against rb 554136

Manufactured by BD
Visit Supplier
Sourced in United States

Antibody against Rb (554136) is a laboratory reagent used to detect the Rb (retinoblastoma) protein in various biological samples. This antibody can be utilized in techniques such as Western blotting, immunohistochemistry, and immunoprecipitation to study the expression and localization of the Rb protein.

Automatically generated - may contain errors

Lab products found in correlation

Abemaciclib, by Selleck Chemicals (2 mentions) Antibodies against cyclin d2 d52f9 and p rb s795, by Cell Signaling Technology (2 mentions) Cyclin d3 ab28283 antibody, by Abcam (2 mentions) Palbociclib, by Selleck Chemicals (2 mentions) Palbociclib s1116, by Selleck Chemicals (1 mentions) C fos e 8, by Santa Cruz Biotechnology (1 mentions) Ribociclib, by Selleck Chemicals (1 mentions)

Close spelling variants of this product

RB (554136)

3 protocols using antibody against rb 554136

1

Cell Cycle Regulation Pathway Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Palbociclib (S1116) and Abemaciclib (S7158) were purchased from Selleck Chemicals (Houston, Texas, USA). Antibodies against HSP90 (H-114), cyclin D1 (A12), CDK6 (C-21), CDK4 (DCS-35), p16 (C-20), p21 (H164), cyclin E (HE12), c-Jun (G4) and c-Fos (E8) were from Santa Cruz Biotechnology; antibodies against cyclin D2 (D52F9) and p-RB (S795) were from Cell Signaling; antibody against SMARCA4 were from Bethyl Laboratories (A300-813A). Antibody against Rb (554136) was from BD Pharmingen. Cyclin D3 (ab28283) antibody was from Abcam. Antibody against SMARCA4 was used with 1:5000 dilution and all others with 1:1000 dilution. Antibodies for IHC and ChIP are listed in the corresponding method section below.
Xue Y., Meehan B., Fu Z., Wang X.Q., Fiset P.O., Rieker R., Levins C., Kong T., Zhu X., Morin G., Skerritt L., Herpel E., Venneti S., Martinez D., Judkins A.R., Jung S., Camilleri-Broet S., Gonzalez A.V., Guiot M.C., Lockwood W.W., Spicer J.D., Agaimy A., Pastor W.A., Dostie J., Rak J., Foulkes W.D, & Huang S. (2019). SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer. Nature Communications, 10, 557.
+ Open protocol
+ Expand
2

Palbociclib and SMARCB1 Antibody Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Palbociclib (S1116) was purchased from Selleck Chemicals (Houston, TX, USA). Antibodies against SMARCB1 (A301-087A) was from Bethyl Laboratories (Montgomery, TX, USA).
Antibody against Rb (554136) was from BD Pharmingen (San Jose, CA, USA). Antibodies used for immunohistochemistry are listed in the method section below.
Xue Y., Zhu X., Meehan B., Venneti S., Martinez D., Morin G., Maïga R.I., Chen H., Papadakis A.I., Johnson R.M., O'Sullivan M.J., Erdreich-Epstein A., Gotlieb W.H., Park M., Judkins A.R., Pelletier J., Foulkes W.D., Rak J, & Huang S. (2020). SMARCB1 loss induces druggable cyclin D1 deficiency via upregulation of MIR17HG in atypical teratoid rhabdoid tumors. The Journal of pathology, 252(1).
+ Open protocol
+ Expand
3

Evaluation of CDK inhibitors in cancer

Check if the same lab product or an alternative is used in the 5 most similar protocols
Palbociclib (S1116), Abemaciclib (S7158), and Ribociclib (S7440) were purchased from Selleck Chemicals (Houston, TX, USA). Antibodies against HSP90 (H-114), Cyclin D1 (M20), CDK6 (C-21), CDK4 (DCS-35), p16 (C-20), p21 (H164), p27 (C19), and cyclin E (HE12) were from Santa Cruz Biotechnology; antibodies against Cyclin D2 (D52F9) and p-RB (S795) were from Cell Signaling; antibody against SMARCA4 were from Bethyl Laboratories (A300-813A). Antibody against RB (554136) was from BD Pharmingen. Cyclin D3 (ab28283) antibody was from Abcam. Antibody against SMARCA4 was used with 1:5000 dilution and all others with 1:1000 dilution. Antibodies for IHC are listed in the corresponding method section below.
Xue Y., Meehan B., Macdonald E., Venneti S., Wang X.Q., Witkowski L., Jelinic P., Kong T., Martinez D., Morin G., Firlit M., Abedini A., Johnson R.M., Cencic R., Patibandla J., Chen H., Papadakis A.I., Auguste A., de Rink I., Kerkhoven R.M., Bertos N., Gotlieb W.H., Clarke B.A., Leary A., Witcher M., Guiot M.C., Pelletier J., Dostie J., Park M., Judkins A.R., Hass R., Levine D.A., Rak J., Vanderhyden B., Foulkes W.D, & Huang S. (2019). CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary. Nature Communications, 10, 558.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!